Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

by | Jun 6, 2023 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.
Read More

Submit a Comment